Dr. Srivastava is a Chairman and Cofounder of the California-based Global Institute of Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California (USA). Several governments and organizations – including the United States, India, China, Turkey, Kuwait, Thailand, Philippines, Bahamas, Saudi Arabia and many others – seek his advice and guidance on drafting their strategic and national policy formulations and program directions in the area of stem cell research, development, and its regulations.
The company was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world such as Parkinson’s disease, Alzheimer’s disease, neuropathy, diabetes, heart disease, stroke, spinal cord injuries, paralysis, and blood related diseases. GIOSTAR is a leader in developing the most advanced stem cell based technology, supported by leading scientists with pioneering publications in the area of stem cell biology. The company’s primary focus is to discover and develop a cure for human diseases, with state-of-the-art, unique stem cell based therapies and products. Regenerative medicine provides promise for treatments of diseases previously regarded as incurable.
Under Dr. Srivastava’s creative leadership, a group of esteemed scientists and clinicians are developing stem cell therapies for various types of autoimmune diseases and blood disorders.
Dr. Anand Srivastava has been associated with leading universities and research institutions throughout the world. In affiliation with University of California San Diego (UCSD) School of Medicine, University of California Irvine (UCI) School of Medicine, The Salk Institute for Biological Studies in San Diego, The Sanford Burnham Prebys Medical Discovery Institute, and University of California, Los Angeles (UCLA) School of Medicine, Dr. Srivastava has developed several research projects. He has extensive research experience in the field of stem cells, which is documented by several publications in revered scientific journals.
Dr. Srivastava’s success is rooted in his unique background and expertise in stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cells, tissue targeting, gene therapy, and clinical research. There are many scientists who can work in a narrowly defined field, but few have the broad and multidisciplinary experience to carry out clinical research in fields as challenging as stem cell biology, cancer, and gene therapy. Dr. Srivastava’s wide-spectrum expertise is rare in clinical research and perfectly crafted to fit ideally with GIOSTAR projects for stem cell transplantation, cancer, and gene therapy research.
Dr. Srivastava’s research work has been presented in various national and international scientific meetings and conferences in India, Japan, Germany, and USA. His research articles have been published in peer-reviewed medical scientific journals, and his work has been cited extensively by other scientists. His expertise and scientific achievements have been recognized by many scientific fellowships, and he has been awarded with the prestigious and internationally recognized Japan International Science and Technology Exchange Center (JISTEC) Award from the Government of Japan. Also, he received the Excellent Presentation Award in the Meeting of Clinical Chemistry and Medicine in Kyoto, Japan.
Dr. Srivastava also has expertise in genetic engineering research, developmental biology, immunology, and the making of transgenic animals. His extraordinary expertise in searching and characterizing new genes is ideal for our ongoing projects of developing effective treatments for many degenerative diseases. Based on his extraordinary scientific achievements, his biography has been included in the “Who’s Who in America” 2018 data bank twice, first in 2005 and again in 2010. He has also received the USA Congressional Recognition for his contribution in the field of stem cell science.
GIOSTAR is already the official collaborator of the Government of Gujarat, India by setting up a state of the art stem cell treatment hospital in Surat civil hospital for the less fortunate tribal populace of the southern belt of Gujarat suffering from sickle cell anemia. Several state governments in India are looking to collaborate with GIOSTAR and Dr. Srivastava in their efforts to develop stem cell transplantation programs in their respective states.